hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06308926, orgStudyIdInfo id: MRG23ARDS, briefTitle: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients, acronym: SUMMIT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2026-07-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: MedRegen LLC, class: INDUSTRY, collaborators name: Vanderbilt University Medical Center, descriptionModule briefSummary: This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS.The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges., conditionsModule conditions: Acute Respiratory Distress Syndrome, conditions: Respiratory Failure, conditions: Respiratory Distress Syndrome, conditions: Respiratory Tract Diseases, conditions: Cytokine Storm, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: MRG-001 (Low-dose), interventions name: MRG-001 (High-dose), interventions name: Placebo, outcomesModule primaryOutcomes measure: Hemopoietic stem cell mobilization, primaryOutcomes measure: Organ Failure, secondaryOutcomes measure: Pharmacokinetics, secondaryOutcomes measure: Pharmacokinetics, secondaryOutcomes measure: Pharmacodynamics, secondaryOutcomes measure: Cytokine Changes, secondaryOutcomes measure: Respiratory-Free Days, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06308913, orgStudyIdInfo id: 2023-1722, secondaryIdInfos id: UW23121, type: OTHER, domain: UWCCC, secondaryIdInfos id: A534260, type: OTHER, domain: UW Madison, secondaryIdInfos id: Protocol Version 2/15/2024, type: OTHER, domain: UW Madison, secondaryIdInfos id: P50DE026787, type: NIH, link: https://reporter.nih.gov/quickSearch/P50DE026787, secondaryIdInfos id: P50CA278595-07, type: NIH, link: https://reporter.nih.gov/quickSearch/P50CA278595-07, briefTitle: Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, collaborators name: National Institute of Dental and Craniofacial Research (NIDCR), collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months., conditionsModule conditions: Head and Neck Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: INCB081776, interventions name: Pembrolizumab, interventions name: Palliative RT, outcomesModule primaryOutcomes measure: Incidence of Adverse Events (AEs), primaryOutcomes measure: Duration of Adverse Events, primaryOutcomes measure: Severity of Adverse Events, secondaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of response (DoR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UW Carbone Cancer Center, city: Madison, state: Wisconsin, zip: 53792, country: United States, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06308900, orgStudyIdInfo id: CL_SIMULATION_01, briefTitle: Non-technical Skills of Clinical Simulation in Physiotherapy Students, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-26, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Valencia, class: OTHER, descriptionModule briefSummary: Clinical simulation has gained great importance in recent times in health sciences. Since it is a pedagogical strategy that is being used more and more in health degrees and is very useful for the acquisition of both technical and non-technical skills.However, if we focus on physiotherapy, the use of clinical simulation is a very new field and therefore requires great research. The investigators still do not have the consistency or experience as in other health branches such as medicine or nursing, in which they have been using simulators for years for the learning of all their students.For all this, and for the situation of need generated in recent years, in which internships in hospitals and clinical centers were completely abolished, the need for our research is justified, which will allow the acquisition of non-technical skills among novice students. in physiotherapy, without the need for contact with real patients., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Clinical simulation, outcomesModule primaryOutcomes measure: Ottawa Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: David Hernández-Guillén, status: RECRUITING, city: Valencia, zip: 46010, country: Spain, contacts name: David Hernández-Guillén, PT, PhD, role: CONTACT, phone: +34644217578, phoneExt: 51232, email: david.hernandez@uv.es, geoPoint lat: 39.46975, lon: -0.37739, hasResults: False
protocolSection identificationModule nctId: NCT06308887, orgStudyIdInfo id: 01, briefTitle: Comparison of Ultrasound-Guided Perimeniscal Steroid and 5% Dextrose Injections in Knee Osteoarthritis, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-02, primaryCompletionDateStruct date: 2024-02-02, completionDateStruct date: 2024-03-02, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Kastamonu University, class: OTHER, descriptionModule briefSummary: Introduction: The primary goal of treating knee osteoarthritis is to reduce pain and improve the patient's quality of life. Medial meniscal extrusion is a condition that is linked to pain and disability in knee osteoarthritis and can be identified through ultrasound. For patients with medial meniscal extrusion, perimeniscal corticosteroid injection has been shown to be a helpful addition to primary treatment for moderate to severe pain relief. Dextrose prolotherapy has also been found to provide periarticular benefits for knee osteoarthritis. This study aims to compare the effectiveness of ultrasound-guided perimeniscal corticosteroid and perimeniscal dextrose injections in patients with osteoarthritis, medial knee pain, and medial meniscal extrusion.Method: Patients with medial knee pain and meniscal extrusion were randomly divided into two groups using the double-block randomization method. Group 1 included 15 patients who were administered an ultrasound-guided perimeniscal steroid injection, while Group 2 included 16 patients who were administered an ultrasound-guided perimeniscal dextrose injection. The patients' pain levels were evaluated using the Visual Analog Pain Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) before and one week, one month, and three months after the injection., conditionsModule conditions: Gonarthrosis, conditions: Meniscus; Degeneration, conditions: Pain, Chronic, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 31, type: ACTUAL, armsInterventionsModule interventions name: Triamcinolone Hexacetonide, interventions name: Dextrose 5% in water, outcomesModule primaryOutcomes measure: Visual Analogue Scale, secondaryOutcomes measure: Western Ontario and McMaster University Osteoarthritis Index, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gamze Gül Güleç, city: Kastamonu, zip: 37150, country: Turkey, geoPoint lat: 41.37805, lon: 33.77528, hasResults: False
protocolSection identificationModule nctId: NCT06308874, orgStudyIdInfo id: JH-222-101, briefTitle: Phase 1 Study to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-02, primaryCompletionDateStruct date: 2023-02-17, completionDateStruct date: 2023-02-17, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: J2H Biotech, class: INDUSTRY, descriptionModule briefSummary: - Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects., conditionsModule conditions: Non-alcoholic Steatohepatitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule interventions name: Amg dose administration group, interventions name: Amg dose administration group- Placebo, interventions name: Bmg dose administration group, interventions name: Bmg dose administration group- Placebo, outcomesModule primaryOutcomes measure: Cmax, primaryOutcomes measure: Emax, eligibilityModule sex: FEMALE, minimumAge: 19 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: J2H Biotech, city: Suwon, state: Gyeonggi-do, zip: 16684, country: Korea, Republic of, geoPoint lat: 37.29111, lon: 127.00889, hasResults: False
protocolSection identificationModule nctId: NCT06308861, orgStudyIdInfo id: JH-201-101, briefTitle: Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-08-12, primaryCompletionDateStruct date: 2021-06-25, completionDateStruct date: 2021-07-13, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: J2H Biotech, class: INDUSTRY, descriptionModule briefSummary: 1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men.2. Design: A dose block-randomized, double-blind, placebo controlled, single- and multiple dosing, dose-escalation phase 1 clinical trial, conditionsModule conditions: Non-alcoholic Steatohepatitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: Single administration Amg dose Group, interventions name: Single administration Bmg dose Group, interventions name: Single administration Cmg dose Group, interventions name: Single administration Dmg dose Group, interventions name: Single administration Emg dose Group, interventions name: Single administration Amg dose Group-Placebo, interventions name: Single administration Bmg dose Group-Placebo, interventions name: Single administration Cmg dose Group-Placebo, interventions name: Single administration Dmg dose Group-Placebo, interventions name: Single administration Emg dose Group-Placebo, interventions name: Multiple administration Amg dose group, interventions name: Multiple administration Bmg dose group, interventions name: Multiple administration Cmg dose group, interventions name: Multiple administration Dmg dose group, interventions name: Multiple administration Emg dose group, interventions name: Multiple administration Amg dose group - Placebo, interventions name: Multiple administration Bmg dose group - Placebo, interventions name: Multiple administration Cmg dose group - Placebo, interventions name: Multiple administration Dmg dose group - Placebo, interventions name: Multiple administration Emg dose group - Placebo, outcomesModule primaryOutcomes measure: Cmax, primaryOutcomes measure: Emax, eligibilityModule sex: MALE, minimumAge: 19 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: J2H Biotech, city: Suwon, state: Gyeonggi-do, zip: 16684, country: Korea, Republic of, geoPoint lat: 37.29111, lon: 127.00889, hasResults: False
protocolSection identificationModule nctId: NCT06308848, orgStudyIdInfo id: PR-22077, briefTitle: Microbiota Directed Food for Children With Severe Acute Malnutrition, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: International Centre for Diarrhoeal Disease Research, Bangladesh, class: OTHER, collaborators name: Washington University School of Medicine, descriptionModule briefSummary: Severe acute malnutrition (SAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing SAM is crucial to prevent its progression to other childhood morbidity and mortality and to ensure healthy child development. To meet the nutritional requirement of SAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use therapeutic food. The investigators propose this proof-of-concept trial to establish evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF., conditionsModule conditions: Severe Acute Malnutrition, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled trial (Proof of concept study), primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Double blind, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 256, type: ESTIMATED, armsInterventionsModule interventions name: Microbiota-Directed Food, interventions name: Ready-to-Use Therapeutic Food, outcomesModule primaryOutcomes measure: Mean change in Weight-for-Length Z-score (WLZ), secondaryOutcomes measure: Gut microbial community repair, secondaryOutcomes measure: Improvement in the levels of plasma protein biomarkers of healthy growth, secondaryOutcomes measure: Mean change in Weight-for-Age Z-score (WAZ), secondaryOutcomes measure: Mean change in Length-for-Age Z-score (LAZ), secondaryOutcomes measure: Mean change in body composition (% body fat mass and % fat-free mass), eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 24 Months, stdAges: CHILD, contactsLocationsModule locations facility: Kurigram Study site, city: Kurigram, country: Bangladesh, contacts name: Md Hasan Hafizur Rahman, MPH, MBBS, role: CONTACT, phone: 01813333444, email: hasan.hafizur@icddrb.org, hasResults: False
protocolSection identificationModule nctId: NCT06308835, orgStudyIdInfo id: APHP231652, briefTitle: Prevalence and Risk Factor of Post-intensive Care Syndrome in Neuro-ICU, acronym: STRESSréa, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Post-intensive care syndrome (PICS) is the set of disabling symptoms that can appear or worsen following a stay in intensive care. These symptoms are physical, cognitive, or psychiatric. The onset and persistence of these symptoms have a major impact on patients' quality of life, their autonomy, and their social and professional reintegration. patients with neurological diseases are frequently excluded from studies due to difficulties for the non-specialist resuscitator to perform the neurological examination and assess whether the symptoms of RPS are secondary to brain damage or complications inherent in resuscitation.The aim of this study is to evaluate the incidence and characteristics of PICS in patients with neurological diseases, at ICU discharge and 3 months after, and to identify the risk factors for developing it., conditionsModule conditions: Post Intensive Care Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: questionnaires, outcomesModule primaryOutcomes measure: Evaluate the presence at 3 months of discharge from an ICU stay for neurological disease of a post intensive care syndrome defined as a physical symptom, primaryOutcomes measure: Evaluate the presence at 3 months of discharge from an ICU stay for neurological disease of a post intensive care syndrome defined as a cognitive symptom, primaryOutcomes measure: Evaluate the presence at 3 months of discharge from an ICU stay for neurological disease of a post intensive care syndrome defined as a psychological symptom, primaryOutcomes measure: Evaluate the presence at 3 months of discharge from an ICU stay for neurological disease of a post intensive care syndrome defined as a psychological symptom., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: GH Pitié Salpêtrière, city: Paris, zip: 75013, country: France, contacts name: Clémence Marois, MD, MSc, role: CONTACT, phone: 0142161858, phoneExt: 33, email: clemence.marois@aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, locations facility: CH Saint Anne, city: Paris, zip: 75014, country: France, contacts name: Camille Legouy, MD, role: CONTACT, phone: 0145656200, phoneExt: 33, email: c.legouy@ghu-paris.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06308822, orgStudyIdInfo id: NCI-2024-01151, secondaryIdInfos id: NCI-2024-01151, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-K1, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-K1, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2018-06-19, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Erdafitinib, interventions name: Magnetic Resonance Imaging, outcomesModule primaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06308809, orgStudyIdInfo id: Shuzhen Ma, briefTitle: Effect of PNF Training as an Intervention for Functional Ankle Instability in College Student, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-06-20, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Ma Shuzhen, class: OTHER, descriptionModule briefSummary: The lower limb stability test was carried out by MicroSwing 6.0 gravity center moving trajectory tester made in Germany., conditionsModule conditions: Adolescent Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Single (Participant)- Page 2 of 5 \[DRAFT\] -In order to avoid mutual interference between the experimental group and the control group, a blinding method needs to be used in the study. In this study, a single blind experiment will be conducted to blind the participating athletes.During the sample grouping process, participating athletes will not know the specific grouping situation., whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: PNF training, outcomesModule primaryOutcomes measure: CAIT score, primaryOutcomes measure: Lower limb stability test, primaryOutcomes measure: Star offset balance test, primaryOutcomes measure: Muscle strength test, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 23 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False